Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 7 de 7
Filtrar
1.
Clin Infect Dis ; 45(2): 187-93, 2007 Jul 15.
Artigo em Inglês | MEDLINE | ID: mdl-17578777

RESUMO

BACKGROUND: Oseltamivir is safe and effective in immunocompetent persons, and prophylactic use is recommended during influenza outbreaks. However, no data exist regarding the use of oseltamivir as prophylaxis among patients undergoing hematopoietic stem cell transplantation (HSCT). METHODS: In January 2002, an influenza A outbreak was identified when 4 cases occurred within 1 week at an outpatient residential facility for patients undergoing HSCT. Oseltamivir prophylaxis (75 mg per day) was initiated for all asymptomatic patients living in the housing facility. Retrospectively, 45 patients (25 of whom had undergone HSCT, and 20 of whom were pre-HSCT candidates) who received oseltamivir prophylaxis were evaluated for adverse events. These 45 patients were matched 1 : 1 with control subjects who received transplants during the period 1994-2003 and did not receive prophylaxis; they were matched according to donor type, conditioning regimen, cytomegalovirus serostatus, time after HSCT, and recipient age (+/-5 years). The frequency of clinical and laboratory adverse events was determined by chart review and graded using National Cancer Institute Common Terminology Criteria. RESULTS: Forty-five residents received oseltamivir for a median of 17 days (range, 10-81 days). No new cases of influenza A occurred in the facility. Seven weeks after initiation of prophylaxis, 1 resident who had been noncompliant to prophylaxis developed an influenza B infection, followed by an additional case of influenza B that occurred in a patient who had not received prophylaxis. No deaths occurred that were attributable to prophylaxis. The proportions of clinical and laboratory adverse events meeting common terminology criteria grades 2-4 or 3-4 were not significantly different between the case patients who received oseltamivir prophylaxis and control subjects. CONCLUSION: Oseltamivir prophylaxis appeared to be safe and well tolerated in managing an influenza outbreak in an HSCT outpatient residence.


Assuntos
Antivirais/uso terapêutico , Neoplasias Hematológicas/terapia , Transplante de Células-Tronco Hematopoéticas , Influenza Humana/prevenção & controle , Oseltamivir/uso terapêutico , Adolescente , Adulto , Idoso , Antivirais/efeitos adversos , Estudos de Casos e Controles , Criança , Relação Dose-Resposta a Droga , Esquema de Medicação , Feminino , Seguimentos , Rejeição de Enxerto , Sobrevivência de Enxerto , Neoplasias Hematológicas/diagnóstico , Neoplasias Hematológicas/imunologia , Humanos , Hospedeiro Imunocomprometido , Influenza Humana/imunologia , Masculino , Pessoa de Meia-Idade , Oseltamivir/efeitos adversos , Probabilidade , Valores de Referência , Estudos Retrospectivos , Medição de Risco , Resultado do Tratamento
2.
Blood ; 110(5): 1681-8, 2007 Sep 01.
Artigo em Inglês | MEDLINE | ID: mdl-17502457

RESUMO

The incidence of respiratory virus infection after hematopoietic cell transplantation (HCT) has probably been underestimated with conventional testing methods in symptomatic patients. This prospective study assessed viral infection episodes by testing weekly respiratory samples collected from HCT recipients, with and without symptoms reported by questionnaire, for 100 days after HCT. Samples were tested by culture and direct fluorescent antibody testing for respiratory syncytial virus (RSV), parainfluenza virus (PIV), and influenza A and B, and by quantitative reverse transcription-polymerase chain reaction for RSV, PIV, influenza A and B, and metapneumovirus (MPV). Of 122 patients, 30 (25%) had 32 infection episodes caused by RSV (5), PIV (17), MPV (6), influenza (3), RSV, or influenza (1). PIV, with a cumulative incidence estimate of 17.9%, was the only virus for which asymptomatic infection was detected. Lower virus copy number in patients with no or one symptom compared with 2 or more symptoms was found for all viruses in all patients (P < .001), with PIV infection having a similar virus-specific comparison (P = .004). Subclinical infection with PIV may help explain why infection-control programs that emphasize symptoms are effective against RSV and influenza but often not against PIV.


Assuntos
Transplante de Células-Tronco Hematopoéticas , Infecções por Paramyxoviridae/epidemiologia , Infecções Respiratórias/epidemiologia , Adolescente , Adulto , Idoso , Animais , Linhagem Celular , Criança , Pré-Escolar , Chlorocebus aethiops , Feminino , Seguimentos , Neoplasias Hematológicas/terapia , Neoplasias Hematológicas/virologia , Humanos , Incidência , Lactente , Controle de Infecções , Masculino , Pessoa de Meia-Idade , Infecções por Paramyxoviridae/diagnóstico , Infecções por Paramyxoviridae/genética , Infecções por Paramyxoviridae/virologia , Estudos Prospectivos , Vírus de RNA/genética , RNA Viral/análise , RNA Viral/genética , Infecções Respiratórias/diagnóstico , Infecções Respiratórias/genética , Infecções Respiratórias/virologia , Reação em Cadeia da Polimerase Via Transcriptase Reversa , Vigilância de Evento Sentinela , Transplante Autólogo , Transplante Homólogo , Cultura de Vírus
3.
J Am Geriatr Soc ; 54(2): 284-9, 2006 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-16460380

RESUMO

OBJECTIVES: To characterize illness and identify the etiology for two nursing home outbreaks of respiratory illness. DESIGN: Multisite outbreak investigations; cohort. SETTING: Two nursing homes in Pennsylvania. PARTICIPANTS: Facility A residents (n = 170), Facility B residents (n = 124), and employees (n = 91). MEASUREMENTS: Medical records for Facility A and B residents were reviewed, and employees from Facility B self-administered a questionnaire to identify risk factors for illness. Serological, oropharyngeal, and nasopharyngeal specimens were collected for both outbreaks, and testing for respiratory pathogens was performed. RESULTS: In Facility A, 40 (24%) of 170 residents were identified with respiratory illness; 13 (33%) case-patients had radiographically confirmed pneumonia, 15 (38%) were taken to a hospital, and two (5%) died. Of 10 specimens collected from symptomatic Facility A case-patients, four (40%) tested positive using reverse transcription polymerase chain reaction for rhinovirus. In Facility B, 77 (62%) of 124 residents had respiratory illness, and 40 (52%) had radiographically confirmed pneumonia; 12 (16%) case-patients were hospitalized, and five (6%) died. Of 19 respiratory specimens collected from symptomatic Facility B case-patients, six (32%) were positive for rhinovirus; one was from an employee. Five (50%) of 10 rhinovirus-positive cases in both outbreaks had clinical and radiographic evidence of pneumonia. CONCLUSION: These investigations suggest that rhinoviruses may be an underrecognized cause of respiratory outbreaks in nursing homes, capable of causing pneumonia and perhaps death.


Assuntos
Surtos de Doenças , Casas de Saúde , Infecções por Picornaviridae/epidemiologia , Infecções Respiratórias/epidemiologia , Rhinovirus , Doença Aguda , Adulto , Idoso , Idoso de 80 Anos ou mais , Anticorpos Antivirais/imunologia , DNA Viral/genética , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Pennsylvania/epidemiologia , Infecções por Picornaviridae/virologia , Infecções Respiratórias/virologia , Rhinovirus/genética , Rhinovirus/imunologia
4.
Pediatr Infect Dis J ; 24(4): 342-51, 2005 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-15818295

RESUMO

BACKGROUND AND OBJECTIVE: Lower respiratory tract infections (LRTIs) cause substantial childhood morbidity. This study characterizes and compares LRTI-associated morbidity among American Indian/Alaska Native (AI/AN) children and the general population of U.S. children. METHODS: Hospitalization and outpatient records with a diagnosis indicating LRTIs were evaluated for children aged younger than 5 years during 1990-2001. RESULTS: For 1999-2001, the LRTI-associated hospitalization rate was significantly higher for AI/AN children than for U.S. children (116.1 versus 63.2/1000, respectively), with the disparity being greater for infants than for 1- to 4-year-old children. Also the rate of LRTI-associated outpatient visits among AI/AN infants was higher than that for all U.S. infants (737.7 versus 207.2/1000, respectively). LRTI hospitalization and outpatient visit rates were highest in the Alaska and Southwest Indian Health Service regions. During 1990-2001, the LRTI hospitalization rate among AI/AN infants in the Alaska region and among the general U.S. infant population increased. Bronchiolitis-associated hospitalization rates increased for AI/AN and U.S. infants, whereas the pneumonia-associated hospitalization rate decreased among AI/AN infants and remained stable among U.S. infants. CONCLUSIONS: LRTIs continue to be an important cause of morbidity in children, especially among AI/AN infants in the Alaska and Southwest regions. Strategies to reduce LRTI hospitalizations and outpatient visits are warranted for all infants, but the greatest potential impact would be among AI/AN infants.


Assuntos
Indígenas Norte-Americanos/estatística & dados numéricos , Inuíte/estatística & dados numéricos , Infecções Respiratórias/etnologia , Infecções Respiratórias/epidemiologia , Distribuição por Idade , Alaska/epidemiologia , Alaska/etnologia , Bronquiolite/epidemiologia , Bronquiolite/etnologia , Criança , Pré-Escolar , Feminino , Hospitalização/estatística & dados numéricos , Humanos , Lactente , Recém-Nascido , Masculino , Pacientes Ambulatoriais/estatística & dados numéricos , Pneumonia/epidemiologia , Pneumonia/etnologia , Distribuição por Sexo , Estados Unidos/epidemiologia
5.
Clin Infect Dis ; 39(5): 673-80, 2004 Sep 01.
Artigo em Inglês | MEDLINE | ID: mdl-15356782

RESUMO

BACKGROUND: Delay of hematopoietic stem cell transplantation (HSCT) has been suggested if upper respiratory tract infection (URTI) due to respiratory syncytial virus (RSV) occurs in transplantation candidates, but the efficacy of this strategy in preventing posttransplantation RSV infection is unknown. METHODS: In a retrospective study, we reviewed charts of patients who underwent transplantation at Fred Hutchinson Cancer Research Center (Seattle, WA) during the period of June 1987 through December 2000 and evaluated the strategy of delaying HSCT in candidates with laboratory-confirmed RSV URTI. RESULTS: Thirty-one of 37 patients had RSV URTI before conditioning, 2 (6.5%) of whom developed RSV infection after HSCT. In 6 of 37 patients, symptoms of URTI were present during the start of conditioning, but RSV virologic confirmation occurred a median of 4.5 days (range, 2-5 days) into the conditioning regimen. Conditioning was aborted for 3 of 6 patients; none had progression to RSV pneumonia. Of the 3 patients in whom HSCT proceeded as scheduled, 2 developed RSV pneumonia. Overall, RSV pneumonia occurred in 1 of 34 patients for whom HSCT was delayed, compared with 2 of 3 patients for whom there was no delay (P=.01). CONCLUSIONS: In patients with pretransplantation RSV URTI, delay of HSCT was associated with a lower risk of pneumonia than was no delay. Because URTIs can progress to severe complications in patients receiving HSCTs, these results support Centers for Disease Control and Prevention/American Society of Blood and Marrow Transplantation recommendations that HSCT be delayed on the basis of symptoms of URTI rather than waiting for virologic confirmation.


Assuntos
Transplante de Células-Tronco Hematopoéticas/métodos , Complicações Pós-Operatórias/virologia , Cuidados Pré-Operatórios/métodos , Infecções por Vírus Respiratório Sincicial/terapia , Vírus Sinciciais Respiratórios/isolamento & purificação , Adolescente , Adulto , Criança , Pré-Escolar , Feminino , Transplante de Células-Tronco Hematopoéticas/mortalidade , Humanos , Lactente , Masculino , Pessoa de Meia-Idade , Agonistas Mieloablativos/uso terapêutico , Infecções por Vírus Respiratório Sincicial/diagnóstico , Infecções por Vírus Respiratório Sincicial/prevenção & controle , Vírus Sinciciais Respiratórios/efeitos dos fármacos , Estudos Retrospectivos , Ribavirina/uso terapêutico , Fatores de Risco , Análise de Sobrevida , Condicionamento Pré-Transplante/métodos , Resultado do Tratamento
6.
Emerg Infect Dis ; 10(2): 217-24, 2004 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-15030686

RESUMO

In early April 2003, severe acute respiratory syndrome (SARS) was diagnosed in a Pennsylvania resident after his exposure to persons with SARS in Toronto, Canada. To identify contacts of the case-patient and evaluate the risk for SARS transmission, a detailed epidemiologic investigation was performed. On the basis of this investigation, 26 persons (17 healthcare workers, 4 household contacts, and 5 others) were identified as having had close contact with this case-patient before infection-control practices were implemented. Laboratory evaluation of clinical specimens showed no evidence of transmission of SARS-associated coronavirus (SARS-CoV) infection to any close contact of this patient. This investigation documents that, under certain circumstances, SARS-CoV is not readily transmitted to close contacts, despite ample unprotected exposures. Improving the understanding of risk factors for transmission will help focus public health control measures.


Assuntos
Síndrome Respiratória Aguda Grave/transmissão , Busca de Comunicante , Fatores Epidemiológicos , Humanos , Masculino , Pessoa de Meia-Idade , Ontário/epidemiologia , Pennsylvania/epidemiologia , Saúde Pública , Fatores de Risco , Síndrome Respiratória Aguda Grave/epidemiologia , Fatores de Tempo , Viagem , Estados Unidos/epidemiologia
7.
Emerg Infect Dis ; 10(2): 244-8, 2004 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-15030690

RESUMO

Healthcare workers accounted for a large proportion of persons with severe acute respiratory syndrome (SARS) during the worldwide epidemic of early 2003. We conducted an investigation of healthcare workers exposed to laboratory-confirmed SARS patients in the United States to evaluate infection-control practices and possible SARS-associated coronavirus (SARS-CoV) transmission. We identified 110 healthcare workers with exposure within droplet range (i.e., 3 feet) to six SARS-CoV-positive patients. Forty-five healthcare workers had exposure without any mask use, 72 had exposure without eye protection, and 40 reported direct skin-to-skin contact. Potential droplet- and aerosol-generating procedures were infrequent: 5% of healthcare workers manipulated a patient's airway, and 4% administered aerosolized medication. Despite numerous unprotected exposures, there was no serologic evidence of healthcare-related SARS-CoV transmission. Lack of transmission in the United States may be related to the relative absence of high-risk procedures or patients, factors that may place healthcare workers at higher risk for infection.


Assuntos
Pessoal de Saúde , Síndrome Respiratória Aguda Grave/transmissão , Adulto , Busca de Comunicante , Surtos de Doenças , Feminino , Humanos , Transmissão de Doença Infecciosa do Paciente para o Profissional , Masculino , Pessoa de Meia-Idade , Fatores de Risco , Síndrome Respiratória Aguda Grave/epidemiologia , Estados Unidos/epidemiologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...